Cushing’s syndrome caused by a metyrapone responsive adrenocortical adenoma

Ronald Crystal, Leslie I. Rose, Paul I. Jagger, David P. Lauler

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The ACTH stimulation test, dexamethasone suppression test and metyrapone stimulation test are useful biochemical tests employed to differentiate disease processes involving increased cortisol production by adrenocortical hyperplasia, adrenocortical adenoma, adrenocortical carcinoma and the ectopic ACTH syndrome. Metyrapone, a pharmacological inhibitor of adrenocortical 11β-hydroxylase activity, partially inhibits cortisol production and thus stimulates ACTH release, resulting in increased urine levels of 17-OHCS. Patients with adrenocortical adenomas are not expected to respond to metyrapone. The present case, with Cushing’s syndrome due to an adrenocortical adenoma, presents an exception to the expected test responses in that there was an increase in urinary 17-OHCS due to administration of metyrapone.

Original languageEnglish
Pages (from-to)199-203
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume31
Issue number2
DOIs
Publication statusPublished - 1 Jan 1970
Externally publishedYes

Fingerprint

Adrenocortical Adenoma
Metyrapone
Cushing Syndrome
Adrenocorticotropic Hormone
Hydrocortisone
Ectopic ACTH Syndrome
Adrenocortical Carcinoma
Mixed Function Oxygenases
Dexamethasone
Hyperplasia
Urine
Pharmacology

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Cushing’s syndrome caused by a metyrapone responsive adrenocortical adenoma. / Crystal, Ronald; Rose, Leslie I.; Jagger, Paul I.; Lauler, David P.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 31, No. 2, 01.01.1970, p. 199-203.

Research output: Contribution to journalArticle

Crystal, Ronald ; Rose, Leslie I. ; Jagger, Paul I. ; Lauler, David P. / Cushing’s syndrome caused by a metyrapone responsive adrenocortical adenoma. In: Journal of Clinical Endocrinology and Metabolism. 1970 ; Vol. 31, No. 2. pp. 199-203.
@article{a33cf8b8a31647f680b16ef7b0f37609,
title = "Cushing’s syndrome caused by a metyrapone responsive adrenocortical adenoma",
abstract = "The ACTH stimulation test, dexamethasone suppression test and metyrapone stimulation test are useful biochemical tests employed to differentiate disease processes involving increased cortisol production by adrenocortical hyperplasia, adrenocortical adenoma, adrenocortical carcinoma and the ectopic ACTH syndrome. Metyrapone, a pharmacological inhibitor of adrenocortical 11β-hydroxylase activity, partially inhibits cortisol production and thus stimulates ACTH release, resulting in increased urine levels of 17-OHCS. Patients with adrenocortical adenomas are not expected to respond to metyrapone. The present case, with Cushing’s syndrome due to an adrenocortical adenoma, presents an exception to the expected test responses in that there was an increase in urinary 17-OHCS due to administration of metyrapone.",
author = "Ronald Crystal and Rose, {Leslie I.} and Jagger, {Paul I.} and Lauler, {David P.}",
year = "1970",
month = "1",
day = "1",
doi = "10.1210/jcem-31-2-199",
language = "English",
volume = "31",
pages = "199--203",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Cushing’s syndrome caused by a metyrapone responsive adrenocortical adenoma

AU - Crystal, Ronald

AU - Rose, Leslie I.

AU - Jagger, Paul I.

AU - Lauler, David P.

PY - 1970/1/1

Y1 - 1970/1/1

N2 - The ACTH stimulation test, dexamethasone suppression test and metyrapone stimulation test are useful biochemical tests employed to differentiate disease processes involving increased cortisol production by adrenocortical hyperplasia, adrenocortical adenoma, adrenocortical carcinoma and the ectopic ACTH syndrome. Metyrapone, a pharmacological inhibitor of adrenocortical 11β-hydroxylase activity, partially inhibits cortisol production and thus stimulates ACTH release, resulting in increased urine levels of 17-OHCS. Patients with adrenocortical adenomas are not expected to respond to metyrapone. The present case, with Cushing’s syndrome due to an adrenocortical adenoma, presents an exception to the expected test responses in that there was an increase in urinary 17-OHCS due to administration of metyrapone.

AB - The ACTH stimulation test, dexamethasone suppression test and metyrapone stimulation test are useful biochemical tests employed to differentiate disease processes involving increased cortisol production by adrenocortical hyperplasia, adrenocortical adenoma, adrenocortical carcinoma and the ectopic ACTH syndrome. Metyrapone, a pharmacological inhibitor of adrenocortical 11β-hydroxylase activity, partially inhibits cortisol production and thus stimulates ACTH release, resulting in increased urine levels of 17-OHCS. Patients with adrenocortical adenomas are not expected to respond to metyrapone. The present case, with Cushing’s syndrome due to an adrenocortical adenoma, presents an exception to the expected test responses in that there was an increase in urinary 17-OHCS due to administration of metyrapone.

UR - http://www.scopus.com/inward/record.url?scp=0014833120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014833120&partnerID=8YFLogxK

U2 - 10.1210/jcem-31-2-199

DO - 10.1210/jcem-31-2-199

M3 - Article

VL - 31

SP - 199

EP - 203

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -